natgillin/translations-raw huggingface dataset:
When the results of the five studies comparing Riprazo taken alone with placebo were looked at together, patients aged under 65 had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Riprazo, from an average of 99.4 mmHg at the start of the study.
Ko so primerjali skupaj rezultate petih študij, v katerih so zdravilo Riprazo kot samostojno zdravilo primerjali s placebom, se je pri bolnikih pod 65 leti starosti po osmih tednih jemanja 150 mg zdravila Riprazo povprečni diastolični tlak, ki je na začetku znašal 99, 4 mmHg, v povprečju znižal za 9, 0 mmHg.
Larger falls were seen in patients aged 65 or over and those taking higher doses of Riprazo.
Pri bolnikih, starih 65 let ali več, in tistih, ki so jemali večje odmerke zdravila Riprazo, so opazili večja znižanja tlaka.
Riprazo also reduced blood pressure in patients with diabetes, patients who were overweight, and those who were over 65 years of age.
Zdravilo Riprazo je krvni tlak znižalo tudi pri bolnikih s sladkorno boleznijo, prekomerno težkih bolnikih in tistih, ki so bili starejši od 65 let.
The studies also showed that Riprazo, when taken in combination with other medicines (especially hydrochlorothiazide), can produce additional decreases in blood pressure compared with those produced by these medicines taken without Riprazo.
Študije so pokazale tudi, da lahko zdravilo Riprazo v kombinaciji z drugimi zdravili (še posebej hidroklorotiazidom) povzroči še dodatna znižanja krvnega tlaka v primerjavi z znižanji tlaka, ki jih imajo ta zdravila brez kombiniranja z zdravilom Riprazo.
The most common side effect with Riprazo (seen in between 1 and 10 patients in 100) is diarrhoea.
Najpogostejši neželeni učinek zdravila Riprazo (opažen med 1 in 10 bolniki od 100) je driska.
For the full list of all side effects reported with Riprazo, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Riprazo, glejte Navodilo za uporabo.
Riprazo should not be used by people who may be hypersensitive (allergic) to aliskiren or any of the other ingredients.
Zdravila Riprazo ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) aliskiren ali katero koli drugo sestavino zdravila.
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Riprazo are greater than its risks for the treatment of essential hypertension.
Odbor za zdravila za uporabo v humani medicini (CHMP) meni, da so koristi zdravila Riprazo pri zdravljenju esencialne hipertenzije večje od z njim povezanih tveganj.
The Committee recommended that Riprazo be given marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom Riprazo.
Other information about Riprazo:
Druge informacije o zdravilu Riprazo:
The European Commission granted a marketing authorisation valid throughout the European Union for Riprazo to Novartis Europharm Limited on 22 August 2007.
Evropska Komisija je dovoljenje za promet z zdravilom Riprazo, veljavno po vsej Evropski uniji, odobrila družbi Novartis Europharm Limited dne 22. avgusta 2007.
The full EPAR for Riprazo can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Riprazo je na voljo tukaj.
EU/ 1/ 07/ 409/ 001 EU/ 1/ 07/ 409/ 002 EU/ 1/ 07/ 409/ 003 EU/ 1/ 07/ 409/ 004 EU/ 1/ 07/ 409/ 005 EU/ 1/ 07/ 409/ 006 EU/ 1/ 07/ 409/ 007 EU/ 1/ 07/ 409/ 008 EU/ 1/ 07/ 409/ 009 EU/ 1/ 07/ 409/ 010 EU/ 1/ 07/ 409/ 011 EU/ 1/ 07/ 409/ 012 EU/ 1/ 07/ 409/ 013 EU/ 1/ 07/ 409/ 014 EU/ 1/ 07/ 409/ 015 EU/ 1/ 07/ 409/ 016 EU/ 1/ 07/ 409/ 017 EU/ 1/ 07/ 409/ 018 EU/ 1/ 07/ 409/ 019 EU/ 1/ 07/ 409/ 020
Številka EU EU/ 1/ 07/ 409/ 001 EU/ 1/ 07/ 409/ 002 EU/ 1/ 07/ 409/ 003 EU/ 1/ 07/ 409/ 004 EU/ 1/ 07/ 409/ 005 EU/ 1/ 07/ 409/ 006 EU/ 1/ 07/ 409/ 007 EU/ 1/ 07/ 409/ 008 EU/ 1/ 07/ 409/ 009 EU/ 1/ 07/ 409/ 010 EU/ 1/ 07/ 409/ 011 EU/ 1/ 07/ 409/ 012 EU/ 1/ 07/ 409/ 013 EU/ 1/ 07/ 409/ 014 EU/ 1/ 07/ 409/ 015 EU/ 1/ 07/ 409/ 016 EU/ 1/ 07/ 409/ 017 EU/ 1/ 07/ 409/ 018 EU/ 1/ 07/ 409/ 019 EU/ 1/ 07/ 409/ 020
Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo
Izmišljeno ime Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo Riprazo
Light-pink, biconvex, round tablet, imprinted “ IL” on one side and “ NVR” on the other side.
Bikonveksna okrogla tableta svetlo roza barve, z vtisnjeno oznako ‘ IL ’ na eni strani in ‘ NVR ’ na drugi.
Riprazo may be used alone or in combination with other antihypertensive agents (see sections 4.4 and 5.1).
Riprazo se lahko jemlje samostojno ali v kombinaciji z drugimi učinkovinami za zniževanje krvnega tlaka (glejte poglavji 4. 4 in 5. 1).
Grapefruit juice should not be taken together with Riprazo.
Zdravila Riprazo se ne sme jemati skupaj z grenivkinim sokom.
Paediatric patients (below 18 years) Riprazo is not recommended for use in children and adolescents below age 18 due to a lack of data on safety and efficacy (see section 5.2).
Pediatrični bolniki (mlajši od 18 let) Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Riprazo pri otrocih in mladostnikih pod 18 let ni priporočljiva (glejte poglavje 5. 2).
In the event of severe and persistent diarrhoea, Riprazo therapy should be stopped.
V primeru hude ali persistentne driske je treba zdravljenje z zdravilom Riprazo prekiniti.
Sodium and/ or volume depleted patients In patients with marked volume- and/ or salt-depletion (e. g. those receiving high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Riprazo.
Bolniki s pomanjkanjem natrija in/ ali hipovolemijo Pri bolnikih s hudim pomanjkanjem natrija in/ ali hipovolemijo (na primer pri tistih, ki prejemajo velike odmerke diuretikov) lahko po uvedbi zdravljenja z zdravilom Riprazo pride do simptomatske hipotenzije.
This condition should be corrected prior to administration of Riprazo, or the treatment should start under close medical supervision.
Pomanjkanje natrija in/ ali hipovolemijo je treba odpraviti pred aplikacijo zdravila Riprazo ali pa je treba zdravljenje uvajati pod strogim zdravniškim nadzorom.
Renal impairment In clinical studies Riprazo has not been investigated in hypertensive patients with severe renal impairment (serum creatinine ≥ 150 μ mol/ l or 1.70 mg/ dl in women and ≥ 177 μ mol/ l or 2.00 mg/ dl in men and/ or estimated glomerular filtration rate (GFR) < 30 ml/ min), history of dialysis, nephrotic syndrome or renovascular hypertension.
Okvara ledvic V kliničnih študijah zdravila Riprazo niso raziskovali pri hipertenzivnih bolnikih s hudo okvaro ledvic (kreatinin v serumu ≥ 150 μmol/ l oziroma 1, 70 mg/ dl pri ženskah in ≥ 177 μmol/ l oziroma 2, 00 mg/ dl pri moških in/ ali ocenjeno hitrostjo glomerulne filtracije (GFR) < 30 ml/ min), pri bolnikih, ki so se že zdravili z dializo, pri bolnikih z nefrotskim sindromom ali z renovaskularno hipertenzijo.
Caution should be exercised in hypertensive patients with severe renal impairment due to the lack of safety information for Riprazo.
Zaradi pomanjkanja podatkov o varnosti zdravila Riprazo pri hipertenzivnih bolnikih s hudo okvaro ledvic, je pri teh bolnikih potrebna previdnost.
Renal artery stenosis No data are available on the use of Riprazo in patients with unilateral or bilateral renal artery stenosis, or stenosis to a solitary kidney.
Stenoza ledvične arterije Pri bolnikih z enostransko ali obojestransko stenozo ledvične arterije oziroma bolnikih s stenozo ledvične arterije v primeru solitarne ledvice o uporabi zdravila Riprazo ni podatkov.
Riprazo has no known clinically relevant interactions with medicinal products commonly used to treat hypertension or diabetes.
Za zdravilo Riprazo ni znano nobeno klinično pomembno medsebojno delovanje z drugimi zdravili, ki se pogosto uporabljajo za zdravljenje hipertenzije ali sladkorne bolezni.
Co-administration of aliskiren with either valsartan (↓ 28%), metformin (↓ 28%), amlodipine (↑ 29%) or cimetidine (↑ 19%) resulted in between 20% and 30% change in Cmax or AUC of Riprazo.
Zaradi
When administered with atorvastatin, steady-state Riprazo AUC and Cmax increased by 50%.
3 sočasne uporabe z atorvastatinom sta se AUC in Cmax zdravila Riprazo v stanju dinamičnega ravnovesja zvišala za 50%.
Co- administration of Riprazo had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Sočasna uporaba zdravila Riprazo ni pomembno vplivala na farmakokinetične lastnosti atorvastatina, valsartana, metformina in amlodipina.
Digoxin bioavailability may be slightly decreased by Riprazo.
Zdravilo Riprazo lahko nekoliko zmanjša biološko uporabnost digoksina.
3 Preliminary data suggest that irbesartan may decrease Riprazo AUC and Cmax.
Predhodni podatki nakazujejo, da irbesartan lahko zmanjša AUC in Cmax zdravila Riprazo.
In experimental animals, it has been shown that P-gp is a major determinant of Riprazo bioavailability.
Na poskusnih živalih se je pokazalo, da je P- gp glavna determinanta biološke uporabnosti zdravila Riprazo.
John’ s wort, rifampicin) might therefore decrease the bioavailability of Riprazo.
Zato lahko induktorji P- gp (šentjanževka, rifampin) zmanjšajo biološko uporabnost zdravila Riprazo.
John’ s wort, rifampicin) might therefore decrease the bioavailability of Riprazo.
Zato bi lahko induktorji P- gp (šentjanževka, rifampicin) zmanjšali biološko uporabnost zdravila Riprazo.
Potassium and potassium-sparing diuretics Based on experience with the use of other substances that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other substances that may increase serum potassium levels (e. g. heparin) may lead to
Kalij in diuretiki, ki varčujejo s kalijem Na podlagi izkušenj pri uporabi drugih snovi, ki vplivajo na sistem renin- angiotenzin, lahko sočasna uporaba diuretikov, ki varčujejo s kalijem, nadomestkov kalija, nadomestkov soli s kalijem ali drugih snovi, ki lahko zvišajo koncentracijo kalija v serumu (npr. heparina), povzroča zvišanje koncentracije kalija v serumu.
Grapefruit juice should not be taken together with Riprazo.
Grenivkinega soka se ne sme jemati skupaj z zdravilom Riprazo.
Warfarin The effects of Riprazo on warfarin pharmacokinetics have not been evaluated.
Varfarin Učinkov zdravila Riprazo na farmakokinetične lastnosti varfarina niso ocenjevali.
Food intake Meals with a high fat content have been shown to reduce the absorption of Riprazo substantially.
Uživanje hrane Pokazalo se je, da obroki z veliko vsebnostjo maščob bistveno zmanjšajo absorpcijo zdravila Riprazo.
Riprazo was not teratogenic in rats or rabbits (see section 5.3).
Zdravilo Riprazo ni bilo teratogeno pri podganah ali kuncih (glejte poglavje 5. 3).
As for any medicine that acts directly on the RAS, Riprazo should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters (see section 4.3).
Tako kot velja za katerokoli drugo zdravilo, ki deluje neposredno na sistem renin- angiotenzin, tudi zdravila Riprazo ne smete uporabljati v prvem trimesečju nosečnosti oziroma pri ženskah, ki načrtujejo nosečnost, poleg tega je kontraindiciran v drugem in tretjem trimesečju nosečnosti (glejte poglavje 4. 3).
Riprazo has negligible influence on the ability to drive and use machines.
Vpliv zdravila Riprazo na sposobnost vožnje in upravljanja s stroji je zanemarljiv.
Riprazo has been evaluated for safety in more than 7,800 patients, including over 2,300 treated for over 6 months, and more than 1,200 for over 1 year.
Varnost zdravila Riprazo so ocenjevali pri več kot 7. 800 bolnikih, med drugim pri več kot 2. 300 bolnikih, ki so bili zdravljeni več kot 6 mesecev, in pri več kot 1. 200 bolnikih, ki so bili zdravljeni več kot 1 leto.
Treatment with Riprazo resulted in an overall incidence of adverse reactions similar to placebo up to 300 mg.
Pri zdravljenju z zdravilom Riprazo je bila pri odmerkih do 300 mg incidenca vseh neželenih učinkov skupaj podobna kot pri placebu.
The incidence of cough was similar in placebo (0.6%) and Riprazo treated (0.9%) patients.
Incidenca kašlja je bila podobna pri bolnikih, ki so prejemali placebo (0, 6%), in pri bolnikih, ki so bili zdravljeni z zdravilom Riprazo (0, 9%).
Angioedema has occurred during treatment with Riprazo.
Pri zdravljenju z zdravilom Riprazo je prišlo do angioedema.
In controlled clinical trials, angioedema occurred rarely during treatment with Riprazo with rates comparable to treatment with placebo or hydrochlorothiazide.
V kontroliranih kliničnih preskušanjih je med zdravljenjem z zdravilom Riprazo redko prišlo do angioedema in sicer s pogostnostjo, ki je bila primerljiva z zdravljenjem s placebom ali s hidroklorotiazidom.
Laboratory findings In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommonly associated with the administration of Riprazo.
Laboratorijski izvidi V kontroliranih kliničnih študijah je bila uporaba zdravila Riprazo občasno povezana s klinično pomembnimi spremembami standardnih laboratorijskih parametrov.
Increases in serum potassium were minor and infrequent in patients with essential hypertension treated with Riprazo alone (0.9% compared to 0.6% with placebo).
Pri bolnikih z esencialno hipertenzijo, zdravljenih samo z zdravilom Riprazo, je redko in v majhni meri prišlo do zvišanja vrednosti kalija v serumu (0, 9% v primerjavi z 0, 6% pri placebu).
However, in one study where Riprazo was used in combination with an ACEI in a diabetic population, increases in serum potassium were more frequent (5.5%).
4. 9 Preveliko odmerjanje
6 Hypertension In hypertensive patients, once-daily administration of Riprazo at doses of 150 mg and 300 mg provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to trough ratio for diastolic response of up to 98% for the 300 mg dose.
Znižanje krvnega tlaka je bilo odvisno od velikosti odmerka in se je ohranilo skozi celoten 24- urni interval odmerjanja (ohranjena koristnost učinka v zgodnjih jutranjih urah).
Riprazo has been studied in 1,864 patients aged 65 years or older, and in 426 patients aged 75 years or older.
Zdravilo Riprazo so proučevali pri 1. 864 bolnikih, starih 65 let ali več, in pri 426 bolnikih, starih 75 let ali več.
Riprazo monotherapy studies have shown blood pressure lowering effects comparable to other classes of antihypertensive agents including ACEI and ARB.
Rezultati študij zdravila Riprazo v monoterapiji so pokazali učinke zniževanja krvnega tlaka, ki so primerljivi z učinki drugih skupin antihipertenzivnih zdravil, vključno z zaviralci angiotenzinske konvertaze in antagonisti angiotenzina II.
Compared to a diuretic (hydrochlorothiazide - HCTZ), Riprazo 300 mg lowered systolic/ diastolic blood pressure by 17.0/ 12.3 mmHg, compared to 14.4/ 10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
V primerjavi z diuretikom hidroklorotiazidom je Riprazo po 12 tednih zdravljenja v odmerku 300 mg znižal sistolični/ diastolični krvni tlak za 17, 0/ 12, 3 mmHg, hidroklorotiazid v odmerku 25 mg pa za 14, 4/ 10, 5 mmHg.
In diabetic hypertensive patients, Riprazo monotherapy was safe and effective.
Pri sladkornih bolnikih s hipertenzijo je bila monoterapija z zdravilom Riprazo varna in učinkovita.
Combination therapy studies are available for Riprazo added to the diuretic hydrochlorothiazide, the ACEI ramipril, the calcium channel blocker amlodipine, the angiotensin receptor antagonist valsartan, and the beta blocker atenolol.
Izvajali so študije kombiniranega zdravljenja z dodajanjem zdravila Riprazo diuretiku hidroklorotiazidu, zaviralcu angiotenzinske konvertaze ramiprilu, zaviralcu kalcijevih kanalčkov amlodipinu, antagonistu angiotenzina II valsartanu in zaviralcu andrenergičnih receptorjev beta atenololu.
Riprazo induced an additive blood-pressure-lowering effect when added to hydrochlorothiazide and to ramipril.
Če so zdravilo Riprazo dodali hidroklorotiazidu in ramiprilu, je povzročilo aditiven učinek zniževanja krvnega tlaka.
Riprazo in combination with the angiotensin receptor antagonist valsartan showed an additive antihypertensive effect in the study specifically designed to investigate the effect of the combination therapy.
Zdravilo Riprazo je v kombinaciji z antagonistom angiotenzina II valsartanom izrazilo aditiven učinek zniževanja krvnega tlaka v študiji, ki je bila načrtovana posebej za raziskovanje učinka kombinacije zdravil.
In diabetic hypertensive patients, Riprazo provided additive blood pressure reductions when added to ramipril, while the combination of Riprazo and ramipril had a lower incidence of cough (1.8%) than ramipril (4.7%).
Pri sladkornih bolnikih s hipertenzijo je dodatek zdravila Riprazo k zdravljenju z ramiprilom povzročil dodatno znižanje krvnega tlaka, incidenca kašlja pa je bila ob kombinaciji zdravila Riprazo in ramiprila nižja (1, 8%) kot pri zdravljenju samo z ramiprilom (4, 7%).
Excessive hypotension was uncommonly (0.1%) seen in patients with uncomplicated hypertension treated with Riprazo alone.
Pri bolnikih s hipertenzijo brez zapletov, ki so se zdravili samo z zdravilom Riprazo, so občasno (pri 0, 1%) opažali pretirano hipotenzijo.
In a 3-month study of 302 patients with mild stable heart failure, all of whom were receiving standard therapy for stable heart failure, addition of Riprazo 150 mg was well tolerated.
Koncentracije možganskega natriuretičnega peptida (BNP
B-type natriuretic peptide (BNP) levels were reduced by 25% in the Riprazo arm compared to placebo.
- B- type natriuretic peptide) so bile v skupini z zdravilom Riprazo nižje za 25% v primerjavi s
However the clinical significance of this reduction is unknown.
skupino s placebom, vendar klinični pomen tega znižanja ni znan.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Riprazo 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
7 V 6- mesečni študiji, ki je vključevala 599 bolnikov s hipertenzijo, sladkorno boleznijo tipa 2 in nefropatijo, so vsi bolniki prejemali 100 mg losartana in optimizirano antihipertenzivno osnovno zdravljenje.
The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for Riprazo and placebo, respectively.
Dodajanje zdravila Riprazo v odmerku 300 mg je v primerjavi s placebom povzročilo 20- odstotno zmanjšanje razmerja med koncentracijo albumina in kreatinina v urinu (UACR - urinary albumin: creatinine ratio), to je od 58 mg/ mmol na 46 mg/ mmol.
The clinical relevance of a reduction in UACR is not established in the absence of an effect on blood pressure.
Delež bolnikov, ki so imeli UACR zmanjšano za vsaj 50% od izhodiščne vrednosti, je bil pri zdravilu Riprazo 24, 7%, pri placebu pa 12, 5%.
Riprazo did not affect the serum concentration of creatinine but was associated with an increased frequency (4.2% vs.
Kliničnega pomena zmanjšanja UACR niso ugotovili glede na to, da ne vpliva na krvni tlak.
1.9% for placebo) of serum potassium concentration (≥ 6.0 mmol/ l), although this was not statistically significant.
Zdravilo Riprazo ni vplivalo na koncentracijo kreatinina v serumu, povezano pa je bilo z večjo pogostnostjo (4, 2% v primerjavi z 1, 9% pri placebo) koncentracije kalija v serumu (≥ 6, 0 mmol/ l), čeprav razlika ni bila statistično značilna.
7 Beneficial effects of Riprazo on mortality and cardiovascular morbidity and target organ damage are currently unknown.
Ugodni vplivi zdravila Riprazo na umrljivost, kardiovaskularno obolevnost in prizadetost tarčnih organov trenutno niso znani.
9 Packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.
Pakiranja vsebujejo po 7, 14, 28, 30, 50, 56, 84, 90, 98 ali 280 tablet.
Light-red, biconvex, ovaloid tablet, imprinted “ IU” on one side and “ NVR” on the other side.
Bikonveksna ovalna tableta svetlo rdeče barve, z vtisnjeno oznako ‘ IU ’ na eni strani in ‘ NVR ’ na drugi.
When administered with atorvastatin, steady-state Riprazo AUC and Cmax increased by 50%.
12 sočasne uporabe z atorvastatinom sta se AUC in Cmax zdravila Riprazo v stanju dinamičnega ravnovesja zvišala za 50%.
12 Preliminary data suggest that irbesartan may decrease Riprazo AUC and Cmax.
Predhodni podatki nakazujejo, da irbesartan lahko zmanjša AUC in Cmax zdravila Riprazo.
15 Hypertension In hypertensive patients, once-daily administration of Riprazo at doses of 150 mg and 300 mg provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to trough ratio for diastolic response of up to 98% for the 300 mg dose.
Znižanje krvnega tlaka je bilo odvisno od velikosti odmerka in se je ohranilo skozi celoten 24- urni interval odmerjanja (ohranjena koristnost učinka v zgodnjih jutranjih urah).
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Riprazo 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
16 V 6- mesečni študiji, ki je vključevala 599 bolnikov s hipertenzijo, sladkorno boleznijo tipa 2 in nefropatijo, so vsi bolniki prejemali 100 mg losartana in optimizirano antihipertenzivno osnovno zdravljenje.
16 Beneficial effects of Riprazo on mortality and cardiovascular morbidity and target organ damage are currently unknown.
Ugodni vplivi zdravila Riprazo na umrljivost, kardiovaskularno obolevnost in prizadetost tarčnih organov trenutno niso znani.
18 Packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.
Pakiranja vsebujejo po 7, 14, 28, 30, 50, 56, 84, 90, 98 ali 280 tablet.
What Riprazo is and what it is used for 2.
Kaj je zdravilo Riprazo in za kaj ga uporabljamo 2.
Before you take Riprazo 3.
Kaj morate vedeti, preden boste vzeli zdravilo Riprazo 3.
How to take Riprazo 4.
Kako jemati zdravilo Riprazo 4.
How to store Riprazo 6.
Shranjevanje zdravila Riprazo 6.
WHAT RIPRAZO IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO RIPRAZO IN ZA KAJ GA UPORABLJAMO
Riprazo belongs to a new class of medicines called renin inhibitors.
Zdravilo Riprazo sodi v novo skupino zdravil z imenom zaviralci renina.
Riprazo helps to lower high blood pressure.
Riprazo pomaga zniževati visok krvni tlak.
BEFORE YOU TAKE RIPRAZO
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO RIPRAZO
Do not take Riprazo
Ne jemljite zdravila Riprazo
If you
- če ste alergični (preobčutljivi) na aliskiren ali katerokoli sestavino zdravila Riprazo; če mislite,
Take special care with Riprazo
Bodite posebno pozorni pri uporabi zdravila Riprazo
If any of these apply to you, tell your doctor before you take Riprazo.
Če kaj od navedenega velja za vas, povejte zdravniku, preden začnete jemati zdravilo Riprazo.
The use of Riprazo in children and adolescents is not recommended.
Uporaba zdravila Riprazo pri otrocih in mladostnikih ni priporočena.
Taking Riprazo with food and drink You should take Riprazo with a light meal once a day, preferably at the same time each day.
Jemanje zdravila Riprazo skupaj s hrano in pijačo Zdravilo Riprazo je treba jemati z lahkim obrokom enkrat na dan, najbolje vsak dan ob istem času.
You should not take Riprazo together with grapefruit juice.
Zdravila Riprazo ne jemljite skupaj z grenivkinim sokom.
Pregnancy and breast-feeding Do not take Riprazo if you are pregnant.
Nosečnost in dojenje Če ste noseči, ne jemljite zdravila Riprazo.
Do not breast-feed if you are taking Riprazo.
Če jemljete zdravilo Riprazo, ne smete dojiti.